Results: 231

Eficacia y seguridad del rituximab en el tratamiento de la esclerosis múltiple: una postura racional en el contexto colombiano

Acta neurol. colomb; 37 (3), 2021
RESUMEN INTRODUCCIÓN: La esclerosis múltiple es una enfermedad neuroinflamatoria, crónica, degenerativa e incurable, asociada a pérdida neuronal, grados crecientes de discapacidad y deterioro cognoscitivo. Su manejo conlleva grandes costos para los sistemas de salud y la sociedad en general. OBJETI...

Serum YKL-40 levels in patients with multiple sclerosis

Arq. neuropsiquiatr; 79 (9), 2021
ABSTRACT Background: Multiple sclerosis (MS) is a chronic inflammatory disease affecting the central nervous system. The YKL-40 protein, which is secreted from various cells that contribute to inflammation and infection, plays a role in immune regulation. Objective: This study investigated the serum YK...

Síndrome de uno y medio
One and a half syndrome

Rev. cuba. oftalmol; 34 (3), 2021
Se realizó una revisión bibliográfica con el objetivo de obtener información actualizada acerca de las características, diagnóstico y tratamiento del síndrome del uno y medio. Se emplearon principalmente las bases de datos disponibles en Infomed, Google Scholar y Pubmed. El síndrome del uno y med...

Estrategia para el seguimiento multidisciplinario a pacientes con esclerosis múltiple

Edumecentro; 13 (3), 2021
RESUMEN Fundamento: la promoción de salud puede ser interpretada como un nuevo camino, una estrategia, una filosofía o una forma diferente de pensar y actuar para alcanzar la salud de los pueblos. La esclerosis múltiple es una enfermedad desmielinizante neurológica que requiere seguimiento a largo p...

Prevalence of multiple sclerosis in key cities of Brazil: a study in Passo Fundo, Southern Brazil

Arq. neuropsiquiatr; 79 (8), 2021
ABSTRACT Background: To improve the comparability of multiple sclerosis (MS) prevalence across Brazilian regions, the Brazilian Committee for Treatment and Research in MS has implemented a standardized approach to assess the prevalence of the disease in five key cities, which were deemed representative ...

Regional brain atrophy is related to social cognition impairment in multiple sclerosis

Arq. neuropsiquiatr; 79 (8), 2021
ABSTRACT Background: Multiple sclerosis exhibits specific neuropathological phenomena driving to both global and regional brain atrophy. At the clinical level, the disease is related to functional decline in cognitive domains as the working memory, processing speed, and verbal fluency. However, the comp...

Determinants of disability development in patients with multiple sclerosis

Arq. neuropsiquiatr; 79 (6), 2021
Abstract Background: Multiple sclerosis (MS) is one of the most common chronic neurological diseases affecting the central nervous system in young adults. Objective: To investigate demographic and clinical factors that are effective in the development of irreversible disability from the onset of MS, an...

Music-based therapy in rehabilitation of people with multiple sclerosis: a systematic review of clinical trials

Arq. neuropsiquiatr; 79 (6), 2021
Abstract Background: Multiple sclerosis (MS) is a major cause of chronic neurological disability in young adults. An increasing number of controlled studies have assessed the potential rehabilitative effects of new drug-free treatments, complementary to the standard care, including music-based therapy (...

Adherencia al tratamiento de la esclerosis múltiple en un programa de atención médica

Medicina (B.Aires); 81 (3), 2021
Resumen La adherencia al tratamiento prescrito en enfermedades crónicas, como ocurre en la esclerosis múltiple (EM), es un factor crítico para una respuesta terapéutica exitosa. El objetivo de este estudio fue evaluar la asociación entre las variables demográficas y la adherencia al tratamiento en ...

Real-world effectiveness of natalizumab treatment in patients with relapsing multiple sclerosis in Argentina and Chile

Arq. neuropsiquiatr; 79 (5), 2021
ABSTRACT Background: The real-world effectiveness of natalizumab in people with relapsing multiple sclerosis (PwRMS) in Argentina and Chile has not been reported. Objective: To evaluate the effectiveness of natalizumab treatment in PwRMS in Argentina and Chile, in clinical practice. Methods: We conduc...